Maybank’s BUY Case for Addvalue Rests on a Viasat Deal. My Screen Runs on a Different Number Entire

Maybank’s BUY Case for Addvalue Rests on a Viasat Deal. My Screen Runs on a Different Number Entirely.

Third-party validation from a US partner and a zero-dividend balance sheet are two different questions. Only one of them decides if this belongs anywhere near retirement money.

Every BUY call needs a story its believers can repeat with confidence. Maybank’s story is Viasat, new orders, and a name most SGX portfolios have never had reason to check. The story is true. It isn’t the number that decides whether this belongs anywhere near CPF money.

I want to be upfront about something before the numbers: Addvalue’s actual FY2026 results are genuinely strong, revenue up 59.9 percent, net profit up 147.5 percent, and the balance sheet cleaner than it has been in years. None of that is in dispute. What is in dispute is whether “strong results plus a US partnership” answers the specific question a retirement portfolio needs answered, and that turns out to be a narrower question than the one Maybank’s report is answering. 

$Addvalue Tech(A31.SG) 

• The Analyst’s Case
• THE LOAD-BEARING ASSUMPTION
• The Window Is Already Open
• Iggy’s Forensic Screen
• Financial Health Checklist
• Layer 1, Raw Fact
• Layer 2, Historical Benchmark
• Layer 3, Peer Context
• Layer 4, Forward Scenario
• Layer 5, Wallet Impact
• The Dividend Trajectory
• The Forensic Gap
• 🟢 Iggy’s Insight
• What To Watch Next
• 🟢 Iggy’s Insight
• Closing
• Iggy’s Forensic Zone: Zone 5, Red Zone
• Iggy’s Elite Read

The Analyst’s Case

Maybank Research reiterated a BUY on Addvalue Technologies (SGX: A31) on 4 September 2026, keeping its target price at S$0.34, built on 30 times FY27E price-to-sales.

The trigger is US$5.0 million in new orders: US$2.8 million for Inter-Satellite Data Relay System products, US$2.2 million for Advanced Digital Radio System products covering strategic design work and repeat supply of compact software-defined-radio modules to defence-technology customers. The company’s reported orderbook has grown to US$20.2 million.

The centrepiece is Viasat. Viasat will incorporate Addvalue’s IDRS terminals and services into its HaloNet portfolio for US government and government-supplier opportunities, with Addvalue positioned as the lead US-facing provider. Maybank reads this as third-party validation of Addvalue’s space communications capability, and a possible route to longer-duration, recurring orders from US space programmes, including potential exposure to organisations such as NASA. That prospective customer exposure is Maybank’s own reading, not a disclosed Addvalue contract, worth keeping separate from the confirmed order figures above.

The broader thesis frames Addvalue as a beneficiary of two high-growth themes, space communications and drone or anti-drone defence, with ADRS demand expected to strengthen in the second half of 2026 and potentially convert into larger multi-year contracts.

THE LOAD-BEARING ASSUMPTION: Maybank’s S$0.34 target depends on this orderbook converting into recurring, multi-year revenue at margins that justify a 30 times sales multiple, years before any of the Viasat-driven demand has actually been contracted, let alone delivered.

Iggy’s Forensic Screen

Here’s where the analyst’s growth story meets a screen built for a different job entirely. My framework tests whether a stock can fund retirement income. Addvalue has never been asked that question by anyone, including itself.

Financial Health Checklist

Occupancy doesn’t appear on this table. That gate exists for REITs measuring how much of a building is earning rent. Addvalue manufactures satellite communication hardware, so the gate simply has nothing to measure here, not a waived test, an inapplicable one.

Layer 1, Raw Fact. At S$0.199 (4 September 2026, delayed quote, re-confirm against InvestingPro or Comet before this figure locks for publication), Addvalue trades at roughly 108 times trailing earnings against 3.68 billion shares outstanding, a market capitalisation north of S$700 million on FY2026 revenue of US$24.8 million. It pays no dividend and never has. Ordinary dividend yield: zero. Total dividend yield: zero. There is no basis to compute a trailing yield because no trailing distribution exists.

🔒 What’s Next

The balance sheet above clears every gate I run except one, and the one it fails isn’t a margin call, it’s a structural absence. The next section is where that distinction actually decides the verdict.

Layer 2, Historical Benchmark. Three years ago Addvalue was a company still working through legacy borrowings and convertible instruments. FY2026 is the first year those obligations are fully gone, cash rose from US$1.51 million to US$7.26 million within the year, and working capital nearly doubled. That’s a real balance sheet recovery, not a one-quarter snapshot. It’s also a company that has never, in that same stretch, converted profitability into a shareholder distribution of any kind.

Layer 3, Peer Context. A meaningful SGX peer set for a loss-adjacent, defence-adjacent satellite communications name at this market capitalisation doesn’t really exist locally, most comparable names trade on Nasdaq or in aerospace-heavy markets where growth multiples of this size are ordinary. Against SGX’s own dividend-paying universe, the comparison that matters isn’t peer-to-peer, it’s category-to-category: this stock sits in growth and speculation, not income and preservation, and belongs in a different conversation than the REITs and banks this framework usually screens.

Layer 4, Forward Scenario. If the Viasat relationship converts on schedule and the orderbook compounds the way Maybank projects, Addvalue could plausibly grow into a materially larger, cash-generative business over several years. If it doesn’t, and defence-technology orderbooks are notoriously lumpy and contract-timing dependent, today’s 108 times earnings has nowhere obvious to hide. Either way, that stress test is about growth delivery, not about balance sheet solvency. The fortress balance sheet survives a bad quarter. The valuation does not.

Layer 5, Wallet Impact. For a reader in their 50s or 60s using SGX holdings to fund retirement drawdown, this stock currently returns nothing while you hold it and asks you to be right about a multi-year defence-orderbook story to earn anything at all. That’s a completely legitimate bet for money you don’t need working for you right now. It is not the same bet as a REIT yielding 6 percent that also happens to carry share price risk, and treating “Maybank says BUY” as equivalent guidance across both categories is where retirement portfolios get hurt, not through bad luck on any single stock, but through blending two different jobs money can do into one decision.

And let’s be honest, the balance sheet story is the more comfortable one to write about, genuine debt elimination, genuine cash growth, genuine profit surge. None of it changes what this framework exists to test.

The Dividend Trajectory

There’s no cost-basis story to tell here, no yield-on-cost comparison between an early holder and a fresh buyer, because the distribution line has always read zero. The Legacy Holders versus Fresh Capital framing that applies to a dividend cut or raise doesn’t have a foothold on a stock that has never distributed anything to compare against.

The Forensic Gap

🟢 Iggy’s Insight

A valuation gap only means something if both sides of it are measuring the same thing. Maybank’s S$0.34 target and the current S$0.199 price are both measuring a growth-and-orders story, priced on future sales, not present cash returned to you. That’s a coherent way to value a company like this. It’s also a completely different exercise from the Forensic Gap table you’ll see on a REIT in this newsletter, where I’m comparing a fair value estimate against a price with a dividend backing it the whole time. Here, the entire gap sits on a bet about tomorrow’s contracts, with nothing distributed today to soften the wait. Know which kind of gap you’re looking at before you decide how much of it to trust.

What To Watch Next

Three things actually move this story, and none of them are the Viasat headline itself.

Whether the US$2.8 million and US$2.2 million orders convert into delivered, invoiced revenue on the timeline management implies, rather than sitting as backlog that slips into future years. Orderbooks are promises, not receipts, and the gap between the two is where growth stories usually run into trouble.

Whether the Viasat relationship produces a named, dated contract, rather than remaining a “potential route to recurring orders” framed by the analyst covering the stock. Third-party validation from a partner is real. A signed multi-year agreement is a different, stronger thing, and the piece will treat them as different things until one becomes the other.

Whether management gives any signal on dividend policy going forward, now that the balance sheet has genuinely cleared out its debt. A company with net cash and a fresh problem, deciding how to deploy that cash, is a fair moment to ask the question even if the answer stays no.

🟢 Iggy’s Insight

Notice what actually changed this year and what didn’t. The debt is gone, the cash grew, the profit surged, all genuinely new. What didn’t change is the company’s relationship with its own shareholders on distributions, which has been zero since the year 2000 and gives no signal of changing now. A business can fix its balance sheet completely and still be exactly as unsuited to an income mandate as it was before the fix. Those are two separate report cards, and this year only one of them improved.

Closing

Zone 5, Red Zone (Not an Income Vehicle, No Dividend Policy)

This is a structural verdict, not a business-quality one. Addvalue’s balance sheet clears gearing, coverage, and leverage with real margin, cleaner today than at almost any point in its listed history. None of that changes the fact that a stock paying no dividend fails the 3.2 percent forensic floor by definition, independent of everything else on the page. Zone 5 here means “not built to fund retirement drawdown,” not “financially distressed.” Those are different findings, and this piece has tried to keep them separate throughout rather than letting one borrow the other’s alarm.

But it’s growing 60 percent and profit is up almost 150 percent, isn’t that worth something? It’s worth something to a growth investor with capital that isn’t earmarked for near-term income. It answers a different question than the one this framework exists to ask, and Maybank’s report, read carefully, was never claiming to answer this one either.

Iggy’s Elite Read

My Watchlist Trigger here isn’t the share price or the Maybank target, it’s whether Addvalue’s next results commentary contains the words “dividend policy” in any form, or whether the Viasat relationship produces a named contract with a term attached to it. Either one would change what kind of stock this actually is. Until then, my Forensic Stance treats this as a growth allocation only, sized like one, and kept entirely separate from the income sleeve this framework is built to protect.

YOUR FORENSIC VERDICT, ONE PAGE.

The full audit is above. This is the Iggy Forensic Audit distilled to one A4 page — every number that matters, every flag that triggered, one clear verdict. Save it, print it, pull it out when this stock crosses your radar again, or when you need to refer to these data points for your retirement planning.

Iggy’s Forensic Disclaimer

This content is produced for educational and informational purposes only. I am not a financial advisor — I am a retail investor who applies forensic analysis to my own portfolio and shares that process publicly. Nothing here constitutes a recommendation to buy, sell, or hold any security, and no specific target prices or personalised financial advice are offered. Stocks assessed under Iggy’s Forensic Yield Standard are benchmarked against a 4.7% minimum yield hurdle; stocks flagged as Growth Watch fall below this threshold but demonstrate clean balance sheet metrics and an identifiable growth catalyst — these carry a materially different risk profile and are not suitable as yield replacements for income-dependent investors. All data is sourced from public filings and verified sources; where data is unverified it is explicitly flagged. All investments carry risk, including the potential loss of principal, and past performance is not indicative of future results. If you are making investment decisions involving CPF, SRS, or personal capital, please conduct your own due diligence or consult a MAS-licensed financial adviser before committing funds.